Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
The Journal of Clinical Investigation
|
February 18, 2004
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease
Iris T Chan, Jeffery L Kutok, Ifor R Williams, et al.
Translational Oncology
|
May 1, 2015
Quantification of Tumor Burden in a Genetically Engineered Mouse Model of Lung Cancer by Micro-CT and Automated Analysis
Kai H Barck, Hani Bou-Reslan, Ujjawal Rastogi, et al.
Cancer Cell
|
December 21, 2004
Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity
Clodagh C O'Shea, Leisa Johnson, Bridget Bagus, et al.
Genes & Cancer
|
June 16, 2012
The ect2 rho Guanine nucleotide exchange factor is essential for early mouse development and normal cell cytokinesis and migration
Danielle R Cook, Patricia A Solski, Scott J Bultman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2020
NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes
Anju Singh, Anneleen Daemen, Dorothee Nickles, et al.
Nature Biotechnology
|
May 25, 2010
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
Mallika Singh, Anthony Lima, Rafael Molina, et al.
The Journal of Pathology
|
May 22, 2012
Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models
Mallika Singh, Suzana S Couto, William F Forrest, et al.
The Journal of Clinical Investigation
|
August 16, 2013
Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy
Leisa Johnson, Mahrukh Huseni, Tanya Smyczek, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
The Journal of Clinical Investigation
|
February 18, 2004
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease
Iris T Chan, Jeffery L Kutok, Ifor R Williams, et al.
Translational Oncology
|
May 1, 2015
Quantification of Tumor Burden in a Genetically Engineered Mouse Model of Lung Cancer by Micro-CT and Automated Analysis
Kai H Barck, Hani Bou-Reslan, Ujjawal Rastogi, et al.
Cancer Cell
|
December 21, 2004
Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity
Clodagh C O'Shea, Leisa Johnson, Bridget Bagus, et al.
Genes & Cancer
|
June 16, 2012
The ect2 rho Guanine nucleotide exchange factor is essential for early mouse development and normal cell cytokinesis and migration
Danielle R Cook, Patricia A Solski, Scott J Bultman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2020
NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes
Anju Singh, Anneleen Daemen, Dorothee Nickles, et al.
Nature Biotechnology
|
May 25, 2010
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
Mallika Singh, Anthony Lima, Rafael Molina, et al.
The Journal of Pathology
|
May 22, 2012
Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models
Mallika Singh, Suzana S Couto, William F Forrest, et al.
The Journal of Clinical Investigation
|
August 16, 2013
Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy
Leisa Johnson, Mahrukh Huseni, Tanya Smyczek, et al.
Page
of 2